Morgan, Coinbase Join Forces
JPMorganChase (NYSE: JPM) and Coinbase (NASDAQ: COIN) announced a strategic partnership that they say sets a new standard for customer choice and security in the innovation economy. This collaboration introduces features designed to enhance access and optionality for our mutual customers.This morning’s news release reports the initial phase of the partnership includes new features for mutual customers, including: Direct Bank-to-Wallet Connection: Through JPMorgan’s secure API, Chase customers will be able to seamlessly link their bank accounts to Coinbase wallets. This direct connection will help mutual customers transact with the confidence, security, and privacy they’re used to as customers of Chase.Transfer of Chase Ultimate Rewards Points: Chase customers will be able to transfer their Chase Ultimate Rewards points to their Coinbase Account at one-to-one redemption ratio (100 points equals $1.00 in redemption value). This marks the first time a major credit card rewards program will be used to fund a crypto wallet.Beginning this Fall, the ability to use Chase credit cards on Coinbas. For the first time, customers will have the ability to fund their Coinbase accounts using Chase credit cards.We expect these direct bank-to-wallet and Ultimate Rewards features to go live in 2026, and the ability to use credit cards to fund a Coinbase account in Fall 2025.Shares in JPM gained $2.22 to $299.26, while those for COIN hiked $11.95, or 3.2%, to $383.39.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


